Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study)

Purpose. An expanded access program (PRIDE study) in Italy to provide ranibizumab 0.5 mg to diabetic macular edema (DME) patients, prior to reimbursement. Methods. Open-label, prospective, phase IIIb study. Majority of patients were not treatment-naïve before enrollment. Patients received ranibizuma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Ophthalmol
Main Authors: Menchini, Ugo, Bandello, Francesco, De Angelis, Vincenzo, Ricci, Federico, Bonavia, Luigi, Viola, Francesco, Muscianisi, Elisa, Nicolò, Massimo
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2015
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4532943/
https://ncbi.nlm.nih.gov/pubmed/26294963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/324841
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados